NCT04059783

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

Non-interventional Study on the Onset of Effect of Iberogast in Patients With Functional or Motility-related Gastrointestinal Diseases

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 272 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Several studies have been done on the efficacy of the herbal medicine Iberogast. In this study researcher want to learn more about the time needed for Iberogast to start to work after the patient took the drug. This study plans to enroll 300 adult male and female patients suffering from disturbance of stomach and intestine normal function and treated by their doctor with Iberogast drops. Patients will be asked to document on a diary card the changes of symptom severity of the stomach and intestine complaints and the time needed for the symptoms to improve after drug intake. At the end of the study the treating doctor and the patients will be asked about the overall changes of symptoms. In addition information on the safety of the drug and how well the drug is tolerated by the patients will be collected

Conditions

• Functional Gastrointestinal Disorders

Interventions

Type	Name	Description
DRUG	STW5 (Iberogast®, BAY98-7411)	The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks

Timeline

• Start date: 2008-06-17
• Primary completion: 2010-04-27
• Completion: 2011-02-20
• First posted: 2019-08-16
• Last updated: 2019-09-19

Locations

1 site across 1 country: Germany